Anti-SARS-CoV-2 Immunoglobulin F(ab')2 fragment (Shanghai Serum Bio)

N/A

Report date: 2022/01/06 18:08:19

Base Information

Drug NameAnti-SARS-CoV-2 Immunoglobulin F(ab')2 fragment (Shanghai Serum Bio)
Drug Alias Name抗SARS-CoV-2免疫球蛋白F（ab'）2片段（上海赛伦生物）
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment
Mechanisms of ActionImmunoglobulin replacementsImmunostimulants
TargetsImmunoglobulin
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Serum Bio-Technology Co LtdWuhan Institute Of Virology, Chinese Academy Of SciencesAcademy Of Military Medical Sciences
China Registration ClassN/A

Develop Information

Active CompaniesWuhan Institute Of Virology, Chinese Academy Of SciencesAcademy Of Military Medical SciencesShanghai Serum Bio-Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A